OTCMKTS:TLPPF Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free TLPPF Stock Alerts $10.20 0.00 (0.00%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$10.20▼$10.2550-Day Range$7.45▼$10.2052-Week Range$5.30▼$10.51Volume3,619 shsAverage Volume5,916 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Telix Pharmaceuticals alerts: Email Address Ad Weiss RatingsHe cracked the code to crypto…Juan Villaverde has cracked the code to crypto.Click now for the best way into the newest AI projects About Telix Pharmaceuticals Stock (OTCMKTS:TLPPF)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More TLPPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLPPF Stock News HeadlinesMay 10, 2024 | americanbankingnews.comTelix Pharmaceuticals (OTCMKTS:TLPPF) Shares Up 0.8%April 29, 2024 | seekingalpha.comCLRPF Clarity Pharmaceuticals LtdApril 18, 2024 | markets.businessinsider.comUBS Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)April 16, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited (TLPPF)April 11, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.April 11, 2024 | businesswire.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.March 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Telix Pharmaceuticals Ltd. (TLPPF)March 18, 2024 | finance.yahoo.comQDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical TherapyMarch 11, 2024 | finance.yahoo.comAppointment of Dr Darren Patti to Group Chief Operating OfficerMarch 5, 2024 | markets.businessinsider.comAustralian Stocks: Telix (TLX) Bolsters Supply Chain with AU$126M ARTMS DealFebruary 23, 2024 | markets.businessinsider.comStrong Buy Rating for Telix Pharmaceuticals Amidst Revenue Surge and Market Expansion OpportunitiesFebruary 22, 2024 | msn.comTelix Pharmaceuticals GAAP EPS of A$1.61, revenue of A$502.55MFebruary 7, 2024 | msn.comQSAM to be acquired by Telix for $33.1M plus $90M CVRJanuary 2, 2024 | morningstar.comTelix Pharmaceuticals Ltd Ordinary SharesDecember 26, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 25, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 11, 2023 | finance.yahoo.comFirst Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging AgentDecember 6, 2023 | finance.yahoo.comPositive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCSNovember 8, 2023 | finance.yahoo.comTelix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic RegionOctober 19, 2023 | msn.comTelix Pharmaceuticals reports Q3 resultsOctober 18, 2023 | finance.yahoo.comProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and TolerabilitySeptember 6, 2023 | finance.yahoo.comTelix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANMAugust 24, 2023 | markets.businessinsider.comWilsons Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)August 23, 2023 | msn.comTelix Pharmaceuticals reports 1H resultsAugust 23, 2023 | finance.yahoo.comTelix 2023 Half-Year Results: Revenue and Earnings Growth Marks Transition to a Sustainable Commercial-Stage CompanySee More Headlines Receive TLPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TLPPF CUSIPN/A CIKN/A Webtelixpharma.com Phone61-3-3093-3897FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Christian P. Behrenbruch BEng(Hons) (Age 48)DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director Comp: $431.11kMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $367.94kDr. Andreas Kluge M.D.Ph.D., Chief Medical Advisor & Non-Executive DirectorMr. Richard Valeix M.B.A.Group Chief Commercial OfficerMr. Darren PattiGroup Chief Operating OfficerDr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors TLPPF Stock Analysis - Frequently Asked Questions Should I buy or sell Telix Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Telix Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" TLPPF shares. View TLPPF analyst ratings or view top-rated stocks. How have TLPPF shares performed in 2024? Telix Pharmaceuticals' stock was trading at $6.8750 on January 1st, 2024. Since then, TLPPF shares have increased by 48.4% and is now trading at $10.20. View the best growth stocks for 2024 here. How do I buy shares of Telix Pharmaceuticals? Shares of TLPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TLPPF) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersDoes this make you sick?Allegiance GoldThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
